Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse). The European Medicines Agency (EMA) has granted Clinical Trial Authorization (CTA) for AMUSE, a Phase 1/2 clinical trial evaluating the safety and efficacy of an allogeneic mesenchymal stromal cell (MSC) therapy in patients with systemic sclerosis presenting perioral fibrosis and functional impairment. [Read more…]
Sponsored Content: Press releases may be published as paid or sponsored content. The issuers of these press releases are solely responsible for their content. BioInformant is not responsible for the accuracy or claims made in these announcements and does not endorse the views expressed by their issuers.
Cytora, Made Scientific, and Zeo ScientifiX Partner to Manufacture and Commercialize Cytora’s Allogeneic Stem Cell Therapy in U.S.
Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot Ulcers and Other Indications
PRINCETON, N.J. and DAVIE, Fla. and TEL AVIV, Israel, Jan. 7, 2026 – Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO); and Zeo ScientifiX, Inc. (Zeo), a Florida-based clinical-stage biopharmaceutical company specializing in research, clinical trials, manufacturing and the commercialization, and market access of biologics, today announced a comprehensive strategic partnership to advance and commercialize Cytora’s novel allogeneic, off- the- shelf, human oral mucosal stem cell therapy in the United States. [Read more…]
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies
Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio, and Echo™-Endothelial. The new platforms are designed to advance cell therapies and drive progress across immuno-oncology and regenerative medicine.Building on the success of the Cellistic Echo™-NK manufacturing platform for natural killer (NK) cells, the expanded Cellistic Echo™ portfolio leverages the company’s GMP manufacturing expertise and its EMA-certified, FDA- and PMDA-compliant manufacturing facility. Through dedicated platform development, these capabilities are extended to deliver scalable solutions across additional immune and regenerative cell types.
[Read more…]
TheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture Solutions
Monmouth Junction, NJ and Tokyo, Japan — January 7, 2026 — TheWell Bioscience Inc., a biotechnology company pioneering next-generation animal-free biofunctional hydrogels, and PeptiGrowth Inc., a leader in innovative synthetic peptide growth factors, today announced that the two companies have entered into a Marketing Collaboration Agreement to jointly promote cutting-edge solutions for stem cell culture, organoid development, and cell therapy manufacturing. [Read more…]
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: IL-15 alternative peptide
January 6, 2026, Chiyoda-ku, Tokyo — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jun Minamitani) has successfully developed a novel synthetic peptide called “IL-15 alternative peptide” which is functionally equivalent to recombinant interleukin 15 (IL-15). This product will be on the market in December 2025. [Read more…]
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 118
- Next Page »